Innate Pharma S.A. (traded on Nasdaq and Euronext Paris under the ticker IPHA) maintains a market capitalization fluctuating around $195 million, classifying it as a micro-cap clinical-stage biotechnology enterprise. Its valuation shifts dynamically based on daily clinical trial updates, regulatory milestone announcements, partnership licensing agreements with major pharmaceutical collaborators, and broader investor sentiment toward small-cap oncology equities.